SCA
ABMD

Stonebridge Capital Advisors’s Abiomed Inc ABMD Stock Holding History

Stonebridge Capital Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed – – 1127
2021
Q4 		$0 Buy
+1
New +$338 ﹤0.01% 1080

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Stonebridge Capital Advisors's ABMD Position: Q1 2022 in Review

Stonebridge Capital Advisors sold out of Abiomed Inc (ABMD) in Q1 2022, closing a stake of 1 share.

Stonebridge Capital Advisors first reported a position in ABMD in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 500 funds tracked by Wall St. Rank hold ABMD as of Q1 2022.

  • Stonebridge Capital Advisors reported no remaining Abiomed Inc position as of Q1 2022 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 1 Abiomed Inc share in Q1 2022.
  • Stonebridge Capital Advisors first reported a position in Abiomed Inc in Q4 2021 and held it in 1 quarter.
  • Stonebridge Capital Advisors's Abiomed Inc position peaked at $0 in Q4 2021.
  • 500 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q1 2022, filed 12 May 2022.